Economic benefits of optimizing anchor therapy for rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 51, Issue SUPPL.4, 2012, Pages

  Fautrel, Bruno ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Biologic therapies; Cost savings; Cost effectiveness; Disease modifying antirheumatic drugs (DMARDs); Glucocorticoids; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; PREDNISONE;

ARTICLE; BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT FAILURE; WATCHFUL WAITING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; COST ALLOCATION; COST-BENEFIT ANALYSIS; DRUG COSTS; GLUCOCORTICOIDS; HUMANS;

EID: 84862675917     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes088     Document Type: Article

References (40)

1. Emery P, Salmon M. Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995;54:944-7.
2. Pincus T. Rheumatoid arthritis: a medical emergency? Scand J Rheumatol Suppl 1994;100:21-30.
3. Weinblatt ME. Rheumatoid arthritis: treat now, not later! Ann Intern Med 1996;124:773-4.
4. Sokka T, Kautiainen H, Pincus T et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009;68:1666-72.
5. Franke LC, Ament AJ, van de Laar MA, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27(4 Suppl. 55):S118-23.
6. Fautrel B, Lucier S, de Rosa M et al. Initiation rapide ou tardive des biothé rapies dans les polyarthrites dé butantes: impact é conomiques, à partir des donné es de al cohorte ESPOIR [Early or later initiation of biologics in early rheumatoid arthritis, based on the ESPOIR cohort data.]. Rev Rhum 2010;77S:A68.
7. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-9.
8. Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine 2008;75:408-15.
9. Lundkvist J, Kastäng F, Kobelt G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2011;8(Suppl. 2):S49-60.
10. Fautrel B, Lucier S, Laroche ML et al. Costs for early rheumatoid arthritis patients by type of treatments in France: results from the ESPOIR cohort. Ann Rheum Dis 2010;69(Suppl. 3):351.
11. Descalzo M, Carmona L, Tobias A. Total joint replacement surgery of hip and knee in the biologics era: a time-trend analysis from 1997-2005. Arthritis Rheum 2007; 56(Suppl.):Abstract 834.
12. Momohara S, Inoue E, Ikari K et al. Decrease in orthopaedic operations, including total joint replacements, in patients with rheumatoid arthritis between 2001 and 2007: data from Japanese outpatients in a single institute-based large observational cohort (IORRA). Ann Rheum Dis 2010; 69:312-3.
13. Huscher D, Ziegler S, Koetter I et al. Increasing intensity of treatment and decreasing work disability 2011 to 2007 in patients with rheumatoid arthritis in Germany. Arthritis Rheum 2008;58(Suppl):Abstract 787.
14. Olofsson T, Englund M, Saxne T et al. Decrease in sick leave among RA patients the first 12 months after start of treatment with TNF-antagonists A population-based cohort study. Ann Rheum Dis 2010;69(Suppl. 3):57.
15. Deighton C, Hyrich K, Ding T et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biologic therapy. Rheumatology 2010;49:1197-9.
16. van den Hout WB, Goekoop-Ruiterman YPM, Allaart CF et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:291-9.
17. Boers M. The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout et al. Arthritis Rheum 2009;61:1616-7.
18. Finckh A, Bansback N, Marra CA et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med 2009;151:612-21.
19. Schoels M, Wong J, Scott DL et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
20. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350: 309-18.
21. Landewé RB, Boers M, Verhoeven AC et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
22. van Tuyl LHD, Boers M, Lems WF et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010;69:807-12.
23. Korthals-de Bos I, Van Tulder M, Boers M et al. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone. J Rheumatol 2004;31:1709-16.
24. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoïde Artritis. Br J Rheumatol 1998;37:1102-9.
25. Gorter SL, Bijlsma JW, Cutolo M et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1010-4.
26. Smolen JS, Landewé R, Breeveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
27. Graudal N, Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010;62:2852-63.
28. Kirwan J, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;4:CD006356.
29. da Silva JAP, Jacobs JWG, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-93.
30. Buttgereit F, Doering G, Schaeffler A et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371:205-14.
31. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 2007;56:399-408.
32. Buttgereit F, Doering G, Schaeffler A et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010;69:1275-80.
33. Alten R, Doering G, Cutolo M et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with night-time-release prednisone. J Rheumatol 2010;37: 2025-31.
34. Kirwan JR. Targeting the time of day for glucocorticoid delivery in rheumatoid arthritis. Int J Clin Rheumatol 2011; 6:273-9.
35. Saag KG, Koehnke R, Caldwell JR et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96: 115-23.
36. Ravindran V, Rachapalli S, Choy EH. Safety of mediumto long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis. Rheumatology 2009;48: 807-11.
37. Boers M, Buttgereit F. A simple model that suggests possible cost savings when modified-release prednisone 5mg/day is added to current treatment in patients with active rheumatoid arthritis. Arthritis Rheum 2011; 63(10 Suppl.):S359(Abstract 914).
38. Buttgereit F, Mehta DP, Kirwan JR et al. Low-dose glucocorticoid chronotherapy of rheumatoid arthritis: 12 week efficacy data of 5 mg modified-release (MR) prednisone. Ann Rheum Dis 2010; 69(Suppl. 3):220.
39. National Institute for Health and Clinical Excellence. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE Clinical Guideline. http://www.nice.org.uk/CG79, Vol. 79. London: NICE 2009 (29 March 2012, date last accessed).
40. Bakker MF, Jacobs JW, Welsing PM et al. Low-dose prednisone inclusion into a MTX-based tight control strategy for early rheumatoid arthritis: better control of disease and erosive joint damage. Results from the double-blind randomized CAMERA-II trial. Ann Rheum Dis 2011; 70(Suppl. 3):114.